查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840848

伴侣动物术后疼痛管理治疗市场（按产品类型、动物类型、给药途径和最终用户划分）－2025-2032年全球预测

Companion Animal Postoperative Pain Management Therapeutics Market by Product Type, Animal Type, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，伴侣动物术后疼痛管理治疗市场规模将成长 3.2845 亿美元，复合年增长率为 10.34%。

关键市场统计数据
基准年 2024 1.4946亿美元
预计年份：2025年 1.6465亿美元
预测年份 2032 3.2845亿美元
复合年增长率 (%) 10.34%

权威指导，引领伴侣动物术后疼痛治疗领域不断发展的临床、技术和商业性动态。

伴侣动物的术后疼痛管理已从单一的临床问题发展成为涵盖药理学、手术方案设计和主人教育的多学科交叉领域。临床医师如今需要在疗效、安全性和饲主依从性之间取得平衡，同时也要应对阿片类药物使用方面的监管审查，并不断拓展替代药物选择。因此，治疗决策不仅要考虑犬猫的急性镇痛需求，还要兼顾长期福利、诊所营运成本和供应链实际情况。

同时，缓释性局部麻醉剂和经皮系统等製剂技术的进步正在改变围手术全期工作流程，使镇痛效果更可预测，给药次数更少。这些技术发展与不断变化的临床环境相辅相成。专科医院、日益增长的线上药局管道以及多中心兽医集团正在影响产品的处方、配药和监测方式。因此，相关人员必须整合临床证据、给药途径偏好和最终使用者行为，才能设计出既具有商业性可行性又具有临床疗效的策略。

报告的执行摘要将这些动态置于犬猫术后疼痛治疗的整体背景下进行分析，重点阐述了影响产品应用的临床因素、产品创新轨迹以及产业结构的转变。该报告旨在为决策者提供一个综合观点，以支持其在研发、监管沟通和商业性执行等方面的战术性规划。

不断发展的临床通讯协定、配方突破和不断变化的分销管道如何重新定义伴侣动物的术后疼痛管理

由于临床、技术和分销管道的创新融合，伴侣动物术后疼痛管理的格局正在发生显着变化。临床实务正在加速采用多模态镇痛通讯协定，该方案结合了局部麻醉剂、非类固醇消炎剂和选择性鸦片类药物，旨在优化疼痛管理并减少副作用。这种转变标誌着围手术手术全期计画正朝着基于对疼痛病理生理学更深入理解和实证实践的个体化方向发展。

在技​​术方面，製剂科学正推动长效局部麻醉剂以及经皮和注射给药系统的改进，从而减少给药频率并提高患者依从性。这些进步使得患者能够顺利从医院过渡到居家医疗，并为以便捷性和持续疗效为核心的新产品定位开闢了机会。同时，非类固醇消炎剂化学和标籤的安全创新，以及临床医生教育的改进，正在缓解人们对不利事件的担忧，而这些担忧过去一直限制着积极的术后管理。

在商业方面，除了传统的兽医诊所和零售药局外，随着线上药局的兴起，分销和获取管道也在发生变化。这种通路多元化迫使製造商采用更复杂的供应链和定价策略。此外，强调阿片类药物管理和上市后药物安全检测的监管趋势也在重塑产品生命週期规划。总而言之，这些变化创造了一个更复杂但也充满机会的环境，成功取决于临床可信度、製剂差异化和基于通路的商业化。

2025年关税对伴侣动物镇痛药的药品采购、定价结构和库存策略的综合影响

2025年累积关税的实施，为动物用药品相关人员的供应链和成本管理带来了新的复杂性。关税主导的成本压力迫使製造商和经销商重新评估筹资策略，优先考虑区域供应安全，并尽可能考虑将部分生产环节迁回国内或近岸。因此，采购团队越来越注重供应商多元化，以降低产地集中和关税波动带来的风险。

这些关税的影响不仅限于直接投入成本，还波及价格谈判、库存管理以及与终端用户管道的合约结构。兽医诊所和医疗机构，尤其是规模较小的全科诊所，必须重新调整采购时机和库存缓衝，以降低价格波动的影响。同时，连锁药局和大型专科诊所则拥有更大的议价能力，可以协商基于销售的协议，从而部分抵销关税带来的成本上涨。

此外，关税环境正在加速简化製剂配方和延长保质期产品的讨论，以降低物流成本。过渡策略包括优先考虑保质期更长的产品，增加缓释性的使用以减少重复订购频率，以及调整临床通讯协定，优先考虑那些能够平衡给药复杂性和供应稳定性的治疗方法。最终，2025年的关税趋势凸显了整合商业和供应链规划的必要性，以确保伴侣动物术后镇痛药物的可近性和可负担性。

差异化細項分析揭示了产品类型、动物种类、给药途径和渠道结构如何独特地影响临床应用和商业策略。

对术后镇痛生态系统的详细细分揭示了临床应用、製剂偏好和渠道动态方面的关键差异，这些差异驱动着不同的商业策略。就产品类型而言，该领域主要围绕着局部麻醉剂、非类固醇消炎剂)和鸦片类药物展开，每种药物都具有独特的治疗作用和监管考虑。在局部麻醉剂中，Bupivacaine和Lidocaine等药物用于术中和术后即刻镇痛，缓释性的进步提升了它们的战略价值。 NSAIDs，包括卡洛芬、德拉考昔、非罗考昔和美洛昔康等分子，儘管安全性和给药方式有所不同，但仍是术后疼痛和发炎管理的基石。Buprenornhine、Fentanyl和曲马多等非类固醇消炎剂药物在中度至重度疼痛的治疗中仍然发挥作用，但它们受到日益严格的监管框架的约束，这影响着处方行为。

猫和狗在药理学和行为学方面存在显着差异，这些差异会影响药物的选择、给药方式以及饲主的指导。例如，猫需要特别关注其对非类固醇抗发炎药（NSAIDs）的耐受性和阿片类药物的选择，而狗则可以受益于多种核准的NSAIDs以及成熟的手术全期用药方案。给药途径对用药的接受度和依从性有显着影响。注射剂是医院围手术全期管理的首选；口服药物支持居家治疗；外用药物可缓解局部疼痛，且全身暴露量极小；经皮吸收贴片可提供持久镇痛，适合门诊治疗，也方便饲主使用。

终端用户细分影响药物取得、处方模式和销售点动态。线上药局扩大了药品供应范围，提高了便利性，但也带来了监管合规性和临床医生参与的考量。兽医医院和诊所，包括全科诊所和专科医院，是围手术全期计划和现场管理的关键决策点，而兽用零售药房（包括连锁店和独立药房）在药品上市初期的配药和咨询方面发挥着关键作用。这些相互交织的细分维度为研发优先事项、商业性目标和教育推广提供了依据，确保产品定位符合每个相关人员的临床实际情况和物流偏好。

在全球市场中，监管、临床实践和通路成熟度的区域差异将决定不同的市场进入、商业化和生命週期策略。

区域动态对法规环境、分销架构和临床实践规范有着显着影响，从而在美洲、中东和非洲以及亚太地区创造了独特的商业机会。在美洲，完善的兽医基础设施和宠物主人的高消费水准促进了先进配方和综合围手术全期通讯协定的快速普及。在这种环境下，透过便利性、安全性以及能够引起临床医生和宠物饲主饲主共鸣的显着疗效来实现差异化竞争优势至关重要。

在欧洲、中东和非洲，由于监管差异和市场成熟度不同，药物的采用率也有差异。西欧市场通常采用先进的临床通讯协定，并优先考虑药物安全检测和标籤，而其他一些地区的市场则更注重成本控制和新疗法的分阶段引入。强调动物用药品安全和抗菌药物管理的法律规范也会影响鸦片类药物的使用和非类固醇消炎剂（NSAID）的标籤，进而影响产品推广和教育重点。

亚太地区融合了快速发展的伴侣动物护理标准、对专业兽医服务的巨额投资以及迅速扩张的线上药局网路。该地区一些国家正在加速采纳临床指南，并积极接受能够减少用药剂量和支持门诊治疗的製剂创新。然而，供应链的复杂性和区域监管的特殊性要求制定有针对性的打入市场策略，该策略需考虑註册时间、进口要求和通路合作伙伴的选择。了解这些区域差异对于使临床证据和商业化计划与当地的期望和限制相符至关重要。

成熟製造商、专业创新者和策略伙伴如何推动术后镇痛领域的临床应用、通路进入和产品差异化

伴侣动物术后镇痛治疗领域的竞争格局呈现出多元化的特点，既有成熟的製药企业，也有专注于动物用药品创新领域的专业公司，以及致力于製剂和给药方式创新的新兴生物製药参与企业。现有企业利用其广泛的分销网络和与临床医生的良好关係，在医院和零售通路站稳脚跟；而专业企业则凭藉新型缓释技术、经皮给药系统以及简化围手术全期流程的产品支援服务，实现差异化竞争。

策略活动的核心在于展现临床差异化优势、在医院系统中占据有利的处方地位，以及与连锁兽医诊所和线上经销商建立伙伴关係。此外，那些大力投资上市后安全性监测和临床医师教育的公司往往能够赢得执业医师的信任，因为执业医师更重视可预测的风险效益比。新参与企业和规模较小的专科公司通常采取快速上市策略，利用密集的临床试验、关键意见领袖互动和数位化教育平台来加速产品推广。

合作模式日益普遍，授权、共同促销和分销协议能够帮助企业更快进入市场，克服不同地区的监管障碍。随着商业化管道的日益细分，那些能够根据终端用户偏好调整产品设计的公司——例如，针对专科医院提供注射用缓释性，针对全科医生提供便捷的口服方案——将更有利于赢得临床顾客购买倾向率并获得长期收益。

製造商和经销商可透过切实可行的策略性倡议，协调证据产生、配方设计、供应弹性和通路互动，从而获得竞争优势。

为确保永续优势，产业领导者应采取连贯的、以证据主导的策略，将产品创新与临床通讯协定和通路实际情况结合。首先，应优先产生多模态临床证据，证明局部麻醉剂、非类固醇消炎剂和选择性鸦片类药物的联合应用如何改善患者预后并降低併发症率。高品质、融入实务的临床试验和真实世界资料收集，既能增强对医院和诊所的价值提案，又能支持负责任的药物管理理念。

第二，使製剂策略与终端使用者的工作流程相契合，提供缓释性和经皮方案，以减轻给药负担并提高依从性，并确保注射剂的特性支持高效的手术全期用药。根据全科诊所和专科医院的需求客製化包装、标籤和教育材料，可以提高药物接受度并减少临床诊疗过程中的摩擦。第三，建立具有韧性的供应链模式，考虑关税风险，实现采购多元化，并制定紧急库存策略，以在全球供应中断期间维持供应的连续性。

第四，投资于通路专属的商业模式，平衡与线上药局的合作与深度临床伙伴关係。数位化教育、整合远端医疗的处方支援以及面向诊所的决策支援工具能够促进产品的合理使用。最后，纳入健全的药物安全检测和阿片类药物管理计划，以满足监管要求并建立医务人员的信任。这些措施的结合能够帮助企业将临床信誉转化为可持续的商业性业绩，同时以负责任的方式推进患者照护。

一项结合临床医生访谈、文献综述和主导细分的场景分析的稳健的混合方法研究途径，检验了该领域的相关见解。

本执行摘要的研究结合了多种定性和定量方法，旨在全面了解临床、商业和监管动态。主要研究包括对兽医、全科医生、处方集管理人员和分销主管进行结构化访谈，以了解实际的处方行为、通路偏好和营运限制。次要研究包括对同行评审的兽医临床文献、监管指导文件、公开的製剂资讯和药物安全检测报告进行横断面检索，以确定产品层面的考虑因素和安全性概况。

分析方法包括交叉细分综合分析，旨在描绘产品类型、动物种类、给药途径和终端用户管道之间的相互作用；以及情境分析，以评估供应链中断和关税的影响。我们与临床医生和商业性相关人员举办检验研讨会，检验了假设，并完善了产品定位和市场推广策略的相关建议。在调查方法和资料来源方面，我们专注于整合多源数据，以减少单一来源偏差，并确保研究结果与不同区域环境的相关性。

本文简明扼要地总结了临床创新、监管预期和商业性执行之间的整合，并概述了未来的策略重点。

伴侣动物术后疼痛管理正处于曲折点，临床最佳实践、製剂技术的进步以及商业分销模式的转变，为相关人员创造了新的机会和挑战。多模式镇痛的兴起，以及缓释性局部麻醉剂和经皮给药系统的创新，正在提升我们提供有效且便于饲主使用的疼痛管理方案的能力。同时，监管环境对鸦片类药物管理的重视以及不断变化的收费体系，也对供应链和临床管治提出了更高的要求。

要成功驾驭这个市场格局，需要将严谨的临床证据与通路导向的商业化策略和灵活的筹资策略结合。那些投资于临床医生参与、研发能够解决实际问题的差异化製剂以及建立健全的药物安全检测体系的公司，将更有能力影响处方行为并实现长期应用。简而言之，伴侣动物术后镇痛的未来将惠及那些拥有临床信誉、卓越运作以及明确关注医护人员和宠物饲主需求的机构。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 开发用于犬猫术后长期镇痛的脂质体Bupivacaine製剂
  • 采用整合非类固醇抗发炎药和局部阻断的、减少鸦片类药物使用的多维度疼痛管理通讯协定
  • 穿戴式感测器技术在远端监测宠物术后疼痛行为的应用
  • 人们对再生医学辅助手段（例如干细胞）促进术后復健的兴趣日益浓厚。
  • 越来越多的兽医开始使用大麻二酚製剂来控制伴侣动物在手术过程中的疼痛。
  • 将远端医疗平台整合到术后护理中，用于虚拟疼痛评估和饲主教育。
  • 开发基于药物基因组学的给药工具，用于兽医实践中个体化镇痛方案。
  • 监管方面的进展将加快有条件许可下新型兽用止痛药的核准

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 伴侣动物术后疼痛管理治疗市场（依产品类型划分）

  • 局部麻醉剂
    • Bupivacaine
    • Lidocaine
  • 非类固醇消炎剂
    • 卡洛芬
    • 德拉考昔
    • 非罗昔布
    • 美洛昔康
  • 阿片类药物
    • Buprenornhine
    • Fentanyl
    • 曲马多

9. 伴侣动物术后疼痛管理治疗市场（依动物类型划分）

  • 猫
  • 狗

10. 伴侣动物术后疼痛管理治疗市场（依给药途径划分）

  • 注射
  • 口服
  • 外用
  • 经皮吸收贴片

11. 伴侣动物术后疼痛管理治疗市场（依最终使用者划分）

  • 网路药房
  • 兽医医院和诊所
    • 一般医疗
    • 专科医院
  • 兽药零售药房
    • 连锁药局
    • 独立药房

12. 伴侣动物术后疼痛管理治疗市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 伴侣动物术后疼痛管理治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国伴侣动物术后疼痛管理治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Dechra Pharmaceuticals PLC
    • Norbrook Laboratories Ltd.
    • Vetoquinol SA
    • Ceva Sante Animale SA
    • Virbac SA
    • Johnson & Johnson Services, Inc.
Product Code: MRR-221461476CB6

The Companion Animal Postoperative Pain Management Therapeutics Market is projected to grow by USD 328.45 million at a CAGR of 10.34% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 149.46 million
Estimated Year [2025] USD 164.65 million
Forecast Year [2032] USD 328.45 million
CAGR (%) 10.34%

An authoritative orientation to the evolving clinical, technological, and commercial dynamics shaping postoperative pain therapies for companion animals

Companion animal postoperative pain management has evolved from a narrow clinical concern into a multidisciplinary imperative that spans pharmacology, surgical protocol design, and client education. Clinicians now balance efficacy, safety, and owner compliance while navigating heightened regulatory scrutiny around opioid use and a growing portfolio of alternatives. Consequently, therapeutic decision-making reflects not only the acute analgesic needs of cats and dogs but also longer-term welfare considerations, practice economics, and supply chain realities.

In parallel, advances in formulation technologies, such as extended-release local anesthetics and transdermal systems, are changing perioperative workflows and enabling more predictable analgesia with fewer administrations. These technical developments intersect with evolving practice settings; specialty hospitals, growing online pharmacy channels, and multi-site veterinary groups shape how products are prescribed, dispensed, and monitored. Therefore, stakeholders must synthesize clinical evidence, route-of-administration preferences, and end-user behaviors to design commercially viable and clinically effective strategies.

This report executive summary situates these dynamics within the broader therapeutic landscape for postoperative pain in cats and dogs, highlighting the clinical drivers, product innovation trajectories, and structural industry shifts that influence adoption. The aim is to equip decision-makers with an integrated perspective that supports tactical planning across R&D, regulatory engagement, and commercial execution.

How clinical protocol evolution, formulation breakthroughs, and shifting distribution channels are redefining postoperative pain management for companion animals

The landscape of postoperative pain management in companion animals is undergoing transformative shifts driven by converging clinical, technological, and distribution innovations. Clinically, there is an accelerating adoption of multimodal analgesia protocols that combine local anesthetics, non-steroidal anti-inflammatory drugs, and selective opioid use to optimize pain control while mitigating side effects. This shift represents a more nuanced appreciation of pain pathophysiology and a move toward individualized perioperative plans anchored in evidence-based practice.

Technologically, formulation science is delivering longer-acting local anesthetics and improved transdermal and injectable delivery systems, which reduce dosing frequency and improve owner adherence. These advances enable smoother transitions from hospital to home care and open opportunities for novel product positioning centered on convenience and sustained efficacy. Simultaneously, safety-focused innovation in NSAID chemistry and labeling, combined with better clinician education, is reducing adverse-event concerns that historically limited aggressive postoperative management.

On the commercial side, distribution and access are changing as online pharmacies gain traction alongside traditional veterinary hospitals and retail pharmacies. This diversification of channels compels manufacturers to adopt more sophisticated supply chain and pricing strategies. In addition, regulatory trends emphasizing opioid stewardship and post-market pharmacovigilance are reshaping product lifecycle planning. Taken together, these shifts create a more complex but opportunity-rich environment where clinical credibility, formulation differentiation, and channel-aligned commercialization determine success.

The compound effects of 2025 tariff measures on pharmaceutical sourcing, pricing architecture, and inventory strategies for companion animal analgesics

The introduction of cumulative tariffs in 2025 has added a new layer of complexity to supply chains and cost management for veterinary pharmaceutical stakeholders. Tariff-driven cost pressures have prompted manufacturers and distributors to reevaluate sourcing strategies, prioritize regional supply security, and consider onshoring or nearshoring certain manufacturing steps where feasible. As a result, procurement teams are increasingly focused on supplier diversification to reduce exposure to concentrated origin risks and tariff volatility.

These tariff effects propagate beyond direct input costs; they influence pricing negotiations with end-user channels, inventory management practices, and the structure of contractual agreements. Veterinary hospitals and clinics, especially smaller general practices, have had to reassess purchasing cadence and inventory buffers to mitigate price fluctuations. Meanwhile, chain pharmacies and larger specialty hospitals possess greater leverage to negotiate volume-based arrangements that can partially offset tariff-related cost increases.

Moreover, the tariff environment has accelerated conversations about formulation simplification and longer-dated products to rationalize logistics expenses. Transitional strategies include prioritizing products with durable shelf life, increasing the use of extended-release formulations to reduce reorder frequency, and aligning clinical protocols to favor therapies that balance administration complexity with supply resilience. Ultimately, tariff dynamics in 2025 have underscored the need for integrated commercial and supply-chain planning to maintain access and affordability for postoperative pain therapies in companion animals.

A differentiated segmentation analysis revealing how product types, animal species, administration routes, and channel structures uniquely shape clinical adoption and commercial strategy

A granular segmentation view of the postoperative analgesia ecosystem reveals critical variances in clinical use, formulation preference, and channel dynamics that drive differentiated commercial strategies. When considering product type, the field is structured around local anesthetics, non-steroidal anti-inflammatory drugs, and opioids, each with distinct therapeutic roles and regulatory considerations. Within local anesthetics, agents such as bupivacaine and lidocaine address intraoperative and immediate postoperative pain control, and advances in extended-release formulations magnify their strategic value. Non-steroidal anti-inflammatory drugs encompass molecules including carprofen, deracoxib, firocoxib, and meloxicam, which form the backbone of postoperative pain and inflammation management with varying safety profiles and dosing paradigms. Opioids such as buprenorphine, fentanyl, and tramadol maintain a role for moderate to severe pain but face increasingly stringent stewardship frameworks that influence prescribing behavior.

Animal type further stratifies clinical pathways, as cats and dogs exhibit important pharmacologic and behavioral differences that affect agent selection, dosing, and owner instructions. Cats, for instance, require particular attention to certain NSAID tolerability and opioid choice, while dogs benefit from a broader array of approved NSAID options and established perioperative pathways. Route of administration exerts a powerful influence on adoption and compliance; injectable formulations are favored for perioperative control in hospital settings, oral agents support home-based continuation of therapy, topical options address localized pain with lower systemic exposure, and transdermal patches offer extended analgesia suited to outpatient care and owner convenience.

End-user segmentation shapes access, prescribing patterns, and point-of-sale dynamics. Online pharmacies expand reach and convenience but bring considerations around regulatory compliance and clinician engagement. Veterinary hospitals and clinics, including general practices and specialty hospitals, serve as primary decision points for perioperative planning and on-site administration, while veterinary retail pharmacies-both chain and independent-play a critical role in dispensing and counseling at the point of release. These layered segmentation dimensions inform R&D prioritization, commercial targeting, and educational outreach, ensuring that product positioning aligns with the clinical realities and logistical preferences of each stakeholder group.

Regional variations in regulation, clinical practices, and channel maturity that dictate differentiated entry, commercialization, and lifecycle strategies across global markets

Regional dynamics materially influence regulatory environments, distribution architectures, and clinical practice norms, creating divergent opportunity sets across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established veterinary practice infrastructures and high pet-owner spend support rapid uptake of advanced formulations and comprehensive perioperative protocols, while reimbursement models remain largely private-pay and therefore sensitive to perceived value. This environment favors differentiation through convenience, proven safety, and demonstrable outcomes that resonate with clinicians and owners alike.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varying market maturity produce a patchwork of adoption rates. Western European markets often mirror advanced clinical protocols and prioritize pharmacovigilance and labeling harmonization, whereas some markets in the broader region emphasize cost containment and incremental introductions of novel therapies. Regulatory frameworks that emphasize veterinary drug safety and antimicrobial stewardship also shape opioid access and NSAID labeling, influencing product rollouts and educational priorities.

Asia-Pacific presents a mix of fast-evolving companion animal care standards, significant investment in specialty veterinary services, and a rapidly expanding online pharmacy footprint. Certain countries in the region are accelerating clinical guideline adoption and are highly receptive to formulation innovations that reduce dosing frequency and support outpatient care. However, supply-chain complexity and local regulatory idiosyncrasies require targeted market-entry strategies that account for registration timelines, import requirements, and channel partner selection. Navigating these regional nuances is essential for aligning clinical evidence packages and commercialization plans with local expectations and constraints.

How incumbent manufacturers, specialty innovators, and strategic partners converge to drive clinical adoption, channel access, and product differentiation in postoperative analgesia

Competitive dynamics in the companion animal postoperative pain therapeutic area are characterized by a mix of established pharmaceutical manufacturers, specialty veterinary pharma innovators, and emerging biopharmaceutical entrants focused on formulation and delivery innovation. Incumbent players leverage broad distribution networks and clinician relationships to maintain a presence in hospital and retail channels, while specialized companies differentiate through novel extended-release technologies, transdermal systems, and product support services that simplify perioperative workflows.

Strategic activity centers on demonstrating clinical differentiation, securing favorable formulary positions within hospital systems, and forging partnerships with veterinary chains and online distributors. Additionally, companies that invest in robust post-market safety surveillance and targeted clinician education tend to gain trust among practitioners who prioritize predictable risk-benefit profiles. New entrants and smaller specialists often adopt nimble go-to-market approaches, using focused clinical pilots, key opinion leader engagement, and digital education platforms to accelerate adoption.

Collaborative models are increasingly common, with licensing, co-promotion, and distribution agreements enabling faster market access across regions with divergent regulatory hurdles. As commercialization becomes more channel-specific, companies that align product design with end-user preferences-such as favoring injectable extended-release formulations for specialty hospitals or convenient oral regimens for general practices-are better positioned to capture clinical mindshare and long-term loyalty.

Practical strategic moves for manufacturers and distributors to align evidence generation, formulation design, supply resilience, and channel engagement to gain competitive advantage

Industry leaders should adopt a coherent, evidence-driven strategy that aligns product innovation with clinical protocols and channel realities to secure sustainable advantage. First, prioritize multimodal clinical evidence generation that demonstrates how combinations of local anesthetics, NSAIDs, and selective opioid use improve patient outcomes and reduce complication rates. High-quality, practice-embedded trials and real-world data capture will strengthen value propositions for hospitals and clinics while supporting responsible stewardship narratives.

Second, align formulation strategy with end-user workflows by offering extended-release and transdermal options where they reduce dosing burden and improve compliance, and by ensuring injectable profiles support efficient perioperative use. Tailoring packaging, labeling, and educational materials to the needs of general practices versus specialty hospitals will improve uptake and reduce friction at the point of care. Third, develop resilient supply-chain models that account for tariff risk, favor diversified sourcing, and include contingency inventory strategies to maintain continuity of supply during global disruptions.

Fourth, invest in channel-specific commercial models that balance online pharmacy engagement with deep clinical partnerships. Digital education, telemedicine-aligned prescribing support, and clinic-facing decision aids can enhance appropriate product use. Finally, incorporate robust pharmacovigilance and opioid stewardship programs to meet regulatory expectations and build practitioner trust. Together, these measures will enable companies to convert clinical credibility into durable commercial performance while responsibly advancing patient care.

A robust mixed-methods research approach integrating clinician interviews, literature synthesis, and segmentation-driven scenario analysis to validate sector insights

The research underpinning this executive summary combines multiple qualitative and quantitative approaches to ensure a comprehensive understanding of clinical, commercial, and regulatory dynamics. Primary research included structured interviews with veterinary surgeons, general practitioners, formulary managers, and distribution executives to capture real-world prescribing behaviors, channel preferences, and operational constraints. Secondary research encompassed a cross-section of peer-reviewed veterinary clinical literature, regulatory guidance documents, and publicly available formulation and pharmacovigilance reports to contextualize product-level considerations and safety profiles.

Analytical techniques included cross-segmentation synthesis to map how product types, animal species, administration routes, and end-user channels interact, as well as scenario analysis to evaluate supply-chain disruptions and tariff impacts. Validation workshops with practicing clinicians and commercial stakeholders were used to test hypotheses and refine implications for product positioning and go-to-market tactics. Throughout the methodology, emphasis was placed on triangulating insights across multiple data sources to reduce single-source bias and to ensure relevance across diverse regional contexts.

A concise synthesis of convergence between clinical innovation, regulatory expectations, and commercial execution that outlines strategic priorities for the future

Postoperative pain management for companion animals is at an inflection point where clinical best practices, formulation advances, and shifting commercial channels converge to create new opportunities and obligations for stakeholders. The move toward multimodal analgesia, coupled with innovations in extended-release local anesthetics and transdermal delivery systems, enhances the capacity to deliver effective, owner-friendly pain control. At the same time, regulatory emphasis on opioid stewardship and evolving tariff landscapes demand more sophisticated supply-chain and clinical governance approaches.

Successfully navigating this landscape requires integrating rigorous clinical evidence with channel-aware commercialization and resilient sourcing strategies. Companies that invest in clinician engagement, differentiated formulations that solve practical problems, and robust pharmacovigilance frameworks will be better positioned to influence prescribing behavior and to achieve longer-term adoption. In essence, the future of companion animal postoperative analgesia will reward organizations that pair clinical credibility with operational excellence and a clear focus on practitioner and pet-owner needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of liposomal bupivacaine formulations extending postoperative analgesia in dogs and cats
  • 5.2. Adoption of opioid-sparing multimodal pain management protocols integrating NSAIDs and local blocks
  • 5.3. Emergence of wearable sensor technology for remote monitoring of postoperative pain behaviors in pets
  • 5.4. Growing interest in regenerative medicine adjuncts such as stem cells for enhanced postoperative recovery
  • 5.5. Increasing availability of veterinarian-prescribed cannabidiol preparations for managing surgical pain in companion animals
  • 5.6. Integration of telehealth platforms for virtual pain assessments and owner education in postoperative care
  • 5.7. Development of pharmacogenomic-based dosing tools to personalize analgesic regimens in veterinary practice
  • 5.8. Regulatory advancements facilitating faster approval of novel veterinary analgesics under conditional licensing pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Postoperative Pain Management Therapeutics Market, by Product Type

  • 8.1. Local Anesthetics
    • 8.1.1. Bupivacaine
    • 8.1.2. Lidocaine
  • 8.2. Non-Steroidal Anti-Inflammatory Drugs
    • 8.2.1. Carprofen
    • 8.2.2. Deracoxib
    • 8.2.3. Firocoxib
    • 8.2.4. Meloxicam
  • 8.3. Opioids
    • 8.3.1. Buprenorphine
    • 8.3.2. Fentanyl
    • 8.3.3. Tramadol

9. Companion Animal Postoperative Pain Management Therapeutics Market, by Animal Type

  • 9.1. Cats
  • 9.2. Dogs

10. Companion Animal Postoperative Pain Management Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical
  • 10.4. Transdermal Patch

11. Companion Animal Postoperative Pain Management Therapeutics Market, by End User

  • 11.1. Online Pharmacies
  • 11.2. Veterinary Hospitals And Clinics
    • 11.2.1. General Practices
    • 11.2.2. Specialty Hospitals
  • 11.3. Veterinary Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Companion Animal Postoperative Pain Management Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Postoperative Pain Management Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Postoperative Pain Management Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Elanco Animal Health Incorporated
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Boehringer Ingelheim International GmbH
    • 15.3.5. Dechra Pharmaceuticals PLC
    • 15.3.6. Norbrook Laboratories Ltd.
    • 15.3.7. Vetoquinol SA
    • 15.3.8. Ceva Sante Animale SA
    • 15.3.9. Virbac SA
    • 15.3.10. Johnson & Johnson Services, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA C